Literature DB >> 19664711

The role of the blood-CNS barrier in CNS disorders and their treatment.

Alan M Palmer1.   

Abstract

The physical barrier between blood and the CNS (the blood-brain barrier, the blood-spinal cord barrier and the blood-CSF barrier) protects the CNS from both toxic and pathogenic agents in the blood. It is now clear that disruption of the blood-CNS barrier plays a key role in a number of CNS disorders, particularly those associated with neurodegeneration. Such disruption is inevitably accompanied by inflammatory change, as immune cells and immune mediators gain access to the brain or spinal cord. The blood-CNS barrier also presents a major obstacle for potential CNS medicines. Robust methods to assess CNS permeation are therefore essential for CNS drug discovery, particularly when brain pharmacokinetics are taken into account and especially when such measures are linked to neurochemical, physiological, behavioural or neuroimaging readouts of drug action. Drug candidates can be successfully designed to cross the blood-CNS barrier, but for those that can't there is the possibility of entry with a delivery system that facilitates the movement of drug candidate across the blood-CNS barrier.

Entities:  

Mesh:

Year:  2009        PMID: 19664711     DOI: 10.1016/j.nbd.2009.07.029

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  34 in total

1.  Molecular Mimicry may Underlie a Worm-Associated Epilepsy Syndrome.

Authors:  Kyle A Lyman; Dane M Chetkovich
Journal:  Epilepsy Curr       Date:  2018 May-Jun       Impact factor: 7.500

2.  Expression of the ALS-causing variant hSOD1(G93A) leads to an impaired integrity and altered regulation of claudin-5 expression in an in vitro blood-spinal cord barrier model.

Authors:  Sabrina Meister; Steffen E Storck; Erik Hameister; Christian Behl; Sascha Weggen; Albrecht M Clement; Claus U Pietrzik
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-08       Impact factor: 6.200

Review 3.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

Review 4.  New and emerging immune-targeted drugs for the treatment of multiple sclerosis.

Authors:  Alan M Palmer
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

5.  Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters.

Authors:  Matthew D Hall; Victor W Pike
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

6.  Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles.

Authors:  G T Lesser; M S Beeri; J Schmeidler; D P Purohit; V Haroutunian
Journal:  Curr Alzheimer Res       Date:  2011-05       Impact factor: 3.498

Review 7.  Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements.

Authors:  K K Pulicherla; Mahendra Kumar Verma
Journal:  AAPS PharmSciTech       Date:  2015-01-23       Impact factor: 3.246

8.  Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors.

Authors:  Bernard L Marini; Lydia L Benitez; Andrew H Zureick; Ralph Salloum; Angela C Gauthier; Julia Brown; Yi-Mi Wu; Dan R Robinson; Chandan Kumar; Robert Lonigro; Pankaj Vats; Xuhong Cao; Katayoon Kasaian; Bailey Anderson; Brendan Mullan; Benjamin Chandler; Joseph R Linzey; Sandra I Camelo-Piragua; Sriram Venneti; Paul E McKeever; Kathryn A McFadden; Andrew P Lieberman; Noah Brown; Lina Shao; Marcia A S Leonard; Larry Junck; Erin McKean; Cormac O Maher; Hugh J L Garton; Karin M Muraszko; Shawn Hervey-Jumper; Jean M Mulcahy-Levy; Adam Green; Lindsey M Hoffman; Katie Dorris; Nicholas A Vitanza; Joanne Wang; Jonathan Schwartz; Rishi Lulla; Natasha Pillay Smiley; Miriam Bornhorst; Daphne A Haas-Kogan; Patricia L Robertson; Arul M Chinnaiyan; Rajen Mody; Carl Koschmann
Journal:  Transl Res       Date:  2017-08-10       Impact factor: 7.012

9.  Phenylbutyrate prevents disruption of blood-spinal cord barrier by inhibiting endoplasmic reticulum stress after spinal cord injury.

Authors:  Yulong Zhou; Libing Ye; Binbin Zheng; Sipin Zhu; Hongxue Shi; Hongyu Zhang; Zhouguang Wang; Xiaojie Wei; Daqing Chen; Xiaokun Li; Huazi Xu; Jian Xiao
Journal:  Am J Transl Res       Date:  2016-04-15       Impact factor: 4.060

Review 10.  Development, maintenance and disruption of the blood-brain barrier.

Authors:  Birgit Obermeier; Richard Daneman; Richard M Ransohoff
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.